Amazon (AMZN) (JPM) (LLY) (PFE) (CCL) (DOW) Price Targets Changed

Amazon.com, Inc. (NASDAQ: AMZN), JPMorgan Chase & Co. (NYSE: JPM), Eli Lilly & Co. (NYSE: LLY), Pfizer (NYSE: PFE), Carnival Co. (NYSE: CCL) and The Dow Chemical Company (NYSE: DOW) had price targets on them adjusted by analysts.

Amazon.com, Inc. (AMZN) had its price target lowered by Benchmark Co. to $210.00.

JPMorgan Chase & Co. (JPM) had its price target raised by Citigroup (NYSE:C) to $42.00.

Eli Lilly & Co. (LLY) had its price target raised by Deutsche Bank (NYSE:DB) to $40.00. They have a “Hold” rating on the company.

Pfizer (NYSE: PFE) had its price target raised by Deutsche Bank to $25.00. They have a “Buy” rating on the company.

Carnival Co. (CCL) had its price target lowered by Telsey Advisory Group to $36.00.

The Dow Chemical Company (DOW) had its price target raised by Goldman Sachs (NYSE:GS) to $38.00. They have a “Neutral” rating on the company.

Pfizer (PFE) (MMI) (PRX) (ANGO) (APH) (ART) Ratings Reiterated

Pfizer Inc. (NYSE: PFE), Motorola Mobility (NYSE: MMI), Par Pharmaceutical Companies Incorporated (NYSE: PRX), AngioDynamics (NASDAQ: ANGO), Amphenol Co. (NYSE: APH) and Artio Global Investors Inc. (NYSE: ART) had ratings on them reiterated by analysts.

Goldman Sachs (NYSE:GS) reiterated its "Conviction Buy" rating on Pfizer Inc. (PFE).

Canaccord Genuity reiterated its "Hold" rating on Motorola Mobility (MMI).

UBS AG (NYSE:UBS) reiterated its "Buy" rating on Par Pharmaceutical Companies Incorporated (PRX).

Zacks Investment Research reiterated its "Neutral" rating on AngioDynamics (ANGO). They have a price target of $14.00 on the company.

Goldman Sachs reiterated its "Neutral" rating on Amphenol Co. (APH).

Goldman Sachs reiterated its "Neutral" rating on Artio Global Investors Inc. (ART).

Pfizer (PFE) (PAY) (PNSN) (DOV) (EW) (EXPR) Ratings Reiterated

Pfizer Inc. (NYSE: PFE), Verifone (NYSE: PAY), Penson Worldwide, Inc. (NASDAQ: PNSN), Dover Co. (NYSE: DOV), Edwards Lifesciences (NYSE: EW) and Express, Inc. (NASDAQ: EXPR) had ratings on them reiterated by analysts.

Deutsche Bank (NYSE:DB) reiterated its "Buy" rating on Pfizer Inc. (PFE).

Citigroup (NYSE:C) reiterated its "Buy" rating on Verifone (PAY). They have a price target of $51.00 on the company.

JPMorgan Chase & Co. (NYSE:JPM) reiterated its "Neutral" rating on Penson Worldwide, Inc. (PNSN).

Nomura reiterated its "Buy" rating on Dover Co. (DOV).

Rodman & Renshaw reiterated its "Market Perform" rating on Edwards Lifesciences (EW).

Brean Murray reiterated its "Buy" rating on Express, Inc. (EXPR).

Pfizer (PFE) (NBY) (RNOW) (BCS) (CBS) (COG) Downgraded

Pfizer Inc. (NYSE: PFE), Novabay Pharmaceuticals (NYSE: NBY), RightNow Technologies (NASDAQ: RNOW), Barclays Capital (NYSE: BCS), CBS (NYSE: CBS) and Cabot Oil & Gas (NYSE: COG) were downgraded by analysts.

Pfizer Inc. (PFE) was downgraded by Leerink from an “Outperform” rating to a “Market Perform” rating.

Novabay Pharmaceuticals (NBY) was downgraded by LifeTech Capital to a “Neutral” rating. They have a price target of $1.25 on the company.

RightNow Technologies (RNOW) was downgraded by JMP Securities from an “Outperform” rating to a “Market Perform” rating.

Barclays Capital (BCS) was downgraded by Goldman Sachs (NYSE:GS) from a “Neutral” rating to a “Sell” rating.

CBS (CBS) was downgraded by Nomura from a “Buy” rating to a “Neutral” rating.

Cabot Oil & Gas (COG) was downgraded by Pritchard from a “Buy” rating to a “Neutral” rating.

Pfizer (PFE) (NTAP) (PEG) (DSW) (ABT) (ADSK) Ratings, Price Targets

Pfizer Inc. (PFE), NetApp Inc. (NTAP), Public Service Enterprise Group Inc. (PEG), DSW Inc. (DSW), Abbott Laboratories (ABT) and Autodesk (ADSK) ratings and price targets.

Leerink downgraded Pfizer Inc. (PFE) from an “Outperform” rating to a “Market Perform” rating.

Wunderlich reiterated its “Buy” rating on NetApp Inc. (NTAP). They have a price target of $68.00 on the company.

Ticonderoga raised its price target on Public Service Enterprise Group Inc. (PEG) from $36.00 to $39.00. They have a “Buy” rating on the company.

Citigroup (NYSE:C) downgraded DSW Inc. (DSW) from a “Buy” rating to a “Neutral” rating. They have a price target of $52.00 on the company.

Morgan Stanley (NYSE:MS) reiterated its “Overweight” rating on Abbott Laboratories (ABT).

RBC Capital raised its price target on Autodesk (ADSK) from $30.00 to $35.00. They have a “Sector Perform” rating on the company.

Pfizer (PFE) (ALV) (STX) (ALK) (TSYS) (ABT) Ratings Reiterated

Pfizer Inc (NYSE: PFE), AUTOLIV INC (NYSE: ALV), Seagate (NYSE: STX), Alaska Air (NYSE: ALK), TeleCommunication Systems, Inc. (NASDAQ: TSYS) and Abbott Laboratories (NYSE: ABT) had ratings on them reiterated by analysts.

Morgan Stanley (NYSE:MS) reiterated its "Overweight" rating on Pfizer Inc. (PFE).

Zacks Investment Research reiterated its "Neutral" rating on AUTOLIV Inc. (ALV). They have a price target of $61.00 on the company.

JPMorgan Chase & Co. (NYSE:JPM) reiterated its "Neutral" rating on Seagate (STX). They have a price target of $14.00 on the company.

Rodman & Renshaw reiterated its "Outperform" rating on Alaska Air (ALK). They have a price target of $78.00 on the company.

JPMorgan Chase & Co. reiterated its "Neutral" rating on TeleCommunication Systems, Inc. (TSYS). They have a price target of $6.50 on the company.

Morgan Keegan reiterated its "Overweight" rating on Abbott Laboratories (ABT).

Pfizer (PFE) (HEI) (HII) (PAY) (PAYX) (SNSS) Get New Coverage

Pfizer Inc (NYSE: PFE), HEICO (NYSE: HEI), Huntington Ingalls (NYSE: HII), Verifone (NYSE: PAY), Paychex, Inc. (NASDAQ: PAYX) and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) getting new coverage from analysts.

MKM Partners initiated coverage on Pfizer Inc. (PFE). They placed a “Buy” rating and a price target of $20.50 on the company.

Auriga initiated coverage on HEICO (HEI). They placed a “Buy” rating on the company.

UBS AG (NYSE:UBS) initiated coverage on Huntington Ingalls (HII). They placed a “Neutral” rating and a price target of $24.00 on the company.

Deutsche Bank (NYSE:DB) initiated coverage on Verifone (PAY). They placed a “Hold” rating and a price target of $40.00 on the company.

Deutsche Bank initiated coverage on Paychex, Inc. (PAYX). They placed a “Hold” rating and a price target of $28.00 on the company.

Wedbush initiated coverage on Sunesis Pharmaceuticals, Inc. (SNSS). They placed an “Outperform” rating and a price target of $4.00 on the company.

Pfizer (PFE) (OGE) (NFLX) (ONNN) (MAN) (PBH) Ratings Reiterated

Pfizer Inc (NYSE: PFE), OGE Energy Corp. (NYSE: OGE), Netflix, Inc. (NASDAQ: NFLX), ON Semiconductor (NASDAQ: ONNN), Manpower Inc (NYSE: MAN) and Prestige Brands Holdings Inc. (NYSE: PBH) had ratings on them reiterated by analysts.

Zacks Investment Research reiterated its "Neutral" rating on Pfizer Inc. (PFE). They have a price target of $19.00 on the company.

Ladenburg Thalmann reiterated its "Neutral" rating on OGE Energy Corp. (OGE).

Citigroup (NYSE:C) reiterated its "Buy" rating on Netflix, Inc. (NFLX).

Jefferies (NYSE:JEF) reiterated its "Buy" rating on ON Semiconductor (ONNN).

Zacks Investment Research reiterated its "Neutral" rating on Manpower Inc. (MAN). They have a price target of $38.00 on the company.

Oppenheimer reiterated its "Market Perform" rating on Prestige Brands Holdings Inc. (PBH).

Pfizer (PFE) (DVA) (PEG) (HRB) (HS) EPS Estimates Changed

Pfizer Inc (NYSE: PFE), DaVita Inc. (NYSE: DVA), Public Service Enterprise Group Inc. (NYSE: PEG), H&R Block, Inc. (NYSE: HRB) and HealthSpring, Inc (NYSE: HS) had their EPS estimates adjusted by analysts.

Pfizer Inc. (PFE) ‘s EPS estimates were raised by Jefferies (NYSE:JEF). They have a “Buy” rating on the company.

DaVita Inc. (DVA) ‘s EPS estimates were raised by Goldman Sachs (NYSE:GS). They have a “Buy” rating and a price target of $86.00 on the company.

Public Service Enterprise Group Inc. (PEG) ‘s EPS estimates were raised by Goldman Sachs. They have a “Buy” rating and a price target of $35.00 on the company.

H&R Block, Inc. (HRB) ‘s EPS estimates were cut by Goldman Sachs. They have a “Neutral” rating and a price target of $15.00 on the company.

HealthSpring, Inc. (HS) ‘s EPS estimates were raised by UBS AG (NYSE:UBS). They have a “Buy” rating and a price target of $52.00 on the company.

SPX (SPW) (CSOD) (MSG) (DG) (PFE) (EBAY) Ratings Reiterated

SPX Corp (NYSE: SPW), Cornerstone OnDemand (NASDAQ: CSOD), Madison Square Garden, Inc. (NYSE: MSG), Dollar General (NYSE: DG), Pfizer Inc (NYSE: PFE) and eBay, Inc. (NASDAQ: EBAY) had their ratings reiterated by analysts.

Citigroup (NYSE:C) reiterated a "Hold" rating on SPX Corp. (SPW).

Piper Jaffray (NYSE:PJC) reiterated an "Overweight" rating on Cornerstone OnDemand (CSOD).

Stifel Nicolaus reiterated a "Hold" rating on Madison Square Garden, Inc. (MSG).

Wedbush reiterated an "Outperform" rating on Dollar General (DG).

JPMorgan Chase & Co. (NYSE:JPM) reiterated an "Overweight" rating on Pfizer Inc. (PFE).

Piper Jaffray reiterated a "Neutral" rating on eBay, Inc. (EBAY).

Tiffany (TIF) (BBY) (NCR) (PFE) EPS Estimates Changed

Tiffany (NYSE:TIF), Best Buy (NYSE:BBY), NCR (NYSE:NCR) and Pfizer (NYSE:PFE) EPS estimates adjusted by analysts.

Tiffany (TIF) estimates were raised by Merriman Capital through 2012. They have a "Neutral" rating on the company.

Best Buy (BBY) estimates were cut by Goldman Sachs (NYSE:GS). They have a "Neutral" rating and a price target of $29 on the company.

NCR (NCR) EPS estimates were raised through 2013 at Goldman Sachs. They have a "Buy" rating and price target of $21 on the company.

Pfizer (PFE) EPS estimates were increased by Goldman Sachs through 2015. They have a "Buy" rating and a price target of $22 on the company.

Newmont (NEM) (WY) (SWN) (PCL) (PFE) (OAS) Upgraded

Newmont Mining Co. (NYSE: NEM), Weyerhaeuser (NYSE: WY), Southwestern Energy (NYSE: SWN), Plum Creek Timber Co. (NYSE: PCL), Pfizer Inc (NYSE: PFE) and Oasis Petroleum Inc. (NYSE: OAS) upgraded by analysts.

Weyerhaeuser (WY) was upgraded by UBS AG (NYSE:UBS) from a “Sell” rating to a “Neutral” rating.

Southwestern Energy (SWN) was upgraded by Global Hunter Securities from a “Reduce” rating to a “Neutral” rating. They have a price target of $39.00 on the company.

Plum Creek Timber Co. (PCL) was upgraded by UBS AG from a “Sell” rating to a “Neutral” rating.

Pfizer Inc. (PFE) was upgraded by Argus from a “Hold” rating to a “Buy” rating. They have a price target of $21.00 on the company.

Oasis Petroleum Inc. (OAS) was upgraded by Morgan Keegan from a “Market Perform” rating to an “Outperform” rating. The have a price target of $34.00 on the company.

Newmont Mining Co. (NEM) was upgraded by Stifel Nicolaus from a “Hold” rating to a “Buy” rating. They have a price target of $76.00 on the company.

Pfizer (PFE) (SCCO) (WTI) (STI) (SKT) (MHK) Upgraded

Pfizer Inc (NYSE: PFE), Southern Copper Corp (NASDAQ: SCCO), W&T Offshore, Inc. (NYSE: WTI), SunTrust (NYSE: STI), Tanger Factory Outlet Centers Inc. (NYSE: SKT) and Mohawk Industries, Inc. (NYSE: MHK) were upgraded by analysts.

W&T Offshore, Inc. (WTI) was upgraded by Global Hunter Securities from a “Neutral” rating to an “Accumulate” rating. They have a price target of $30.00 on the company, up from $20.00.

SunTrust (STI) was upgraded by Citigroup (NYSE:C) from a “Neutral” rating to a “Buy” rating. They have a price target of $30.00 on the company.

Southern Copper Corp. (SCCO) was upgraded by JPMorgan Chase & Co. (NYSE:JPM) from a “Neutral” rating to an “Overweight” rating.

Tanger Factory Outlet Centers Inc. (SKT) was upgraded by Hilliard Lyons from a “Neutral” rating to a “Buy” rating. They have a price target of $29.00 on the company.

Pfizer Inc. (PFE) was upgraded by Standpoint Research from a “Hold” rating to a “Buy” rating. They have a price target of $21.00 on the company.

Mohawk Industries, Inc. (MHK) was upgraded by Credit Suisse (NYSE:CS) from an “Underperform” rating to a “Neutral” rating. They have a price target of $50.00 on the company.

Pfizer's (PFE) Cancer Drug Fast-Tracked by FDA

Pfizer's (NYSE:PFE) application to have a review of their lung-cancer drug crizotinib fast-tracked was approved by the Food and Drug Administration

The giant drug maker also announced it has filed for regulatory approval for crizotinib in Japan.

Pfizer is scrambling to strenghthen its pipeline as its flagship drug Lipitor runs out of protection in November and generic competitors are set to flood the market.

What the approval to fast-track the review means is the process will be lowered from the usual 10 months it takes to review a drug to about six months.

According to Pfizer spokesman Chris Loder a decision should come from the FDA by the end of 2011.

Pfizer was trading at $21.08, gaining $0.10, or 0.50, as of 1:52 PM EDT.

Coverage on (CRL) (MTZ) (PWR) (PFE) (MRK) Initiated by Analysts

Charles River Laboratories International Inc. (NYSE:CRL), Mastec Inc. (NYSE:MTZ), Quanta Services Inc. (NYSE:PWR), Pfizer Inc. (NYSE:PFE) and Merck (NYSE:MRK) had coverage initiated on them by analysts.

Deutsche Bank (NYSE:DB) initiated coverage on Charles River Laboratories International Inc. (CRL), starting them off with a "Hold" rating. They lowered their price target from $44 to $41.50 on the company.

FBR Capital Markets initiated coverage on Mastec Inc. (MTZ), starting them off with an "Outperform" rating.

FBR Capital Markets initiated coverage on Quanta Services Inc. (PWR), starting them off with an "Underperform" rating. They lowered their price target from $20 to $19 on the company.

Credit Suisse (NYSE:CS) initiated coverage on Pfizer Inc. (PFE), starting them off with an "Outperform" rating. They placed a price target of $23 on the company.

Credit Suisse initiated coverage on Merck (NYSE:MRK), starting them off with an "Outperform" rating. They placed a price target of $44 on the company.

Pharmaceuticals (LLY) (BMY) (ABT) (PFE) (TEVA) Trade Mixed Tuesday

Shares of pharmaceuticals Eli Lilly (NYSE:LLY), Bristol-Myers Squibb (NYSE:BMY), Abbott Labs (NYSE:ABT), Pfizer (NYSE:PFE) and Teva (NASDAQ:TEVA) closed mixed Tuesday, with the NYSE Drug index ending the session at 331.74.

Leading the drug winners on Tuesday was Eli Lilly (:LLY), which closed at $38.09, gaining $0.78, or 2.09 percent.

Bristol-Myers Squibb (BMY) also had a good Tuesday, closing the session at $28.83, up $0.38, or 1.34 percent.

Next was Abbott Labs (ABT), which closed out at $52.85, rising $0.26, or 0.49 percent.

Pfizer (PFE) was on the other end of the action, plunging $0.58, or 2.76, to end the day at $20.44. Teva was also under pressure, closing at $46.46, down $0.81, or 1.71 percent.

Sears (SHLD) (CSC) Crushed, (PFE) (XOM) (CVX) Fall

Based on low guidance, failure to meet expectations and falling oil prices, Pfizer (NYSE:PFE), Exxon (NYSE:XOM), Chevron (NYSE:CVX), Computer Science (NYSE:CSC) and Sears Holdings (NASDAQ:SHLD) are all down today.

The worst performer of this grouping of stocks is Computer Sciences, which was trading down just below 13 percent on the day. Low guidance of a loss of $1.35 after saying they expected a gain of 14 cents pushed the share price down.

Next was Sears, which was down over 9 percent so far, plunging after it projected a big loss for the fiscal first quarter of the company. Sears had also originally called for a 14 cent gain, adjusting it to a loss of $1.35 to $1.81 a share.

Exxon Mobil and Chevron were both down on the drop in oil prices, both trading down just under 2 percent.

Pfizer is weighing on the Dow, as it is the biggest decliner on the index, falling over 2 percent after the pharmaceutical company beat earnings expectations but reported revenue that fell short of what analysts had been looking for.

Pfizer (NYSE:PFE) was trading at $20.33, down $0.70, or 3.31 percent, as of 1:52 PM EDT.

Dividend Yields for (LLY) (BMY) (MRK) (PFE) (ABT)

Indicated dividend yields for Standard & Poor's 500 Index companies Eli Lilly & Co (LLY), Bristol-Myers Squibb Co (BMY), Merck & Co Inc (MRK), Pfizer Inc (PFE) and Abbott Laboratories (ABT).

These dividend data indicate dividend yields of companies in the Standard & Poor's 500 Index as of Saturday, April 30. The yield is determined by taking the latest declared dividend, annualized and divided by the price of the stock. Payout ratios are calculated based on latest quarterly dividend paid divided by earnings.

Eli Lilly & Co (LLY) has a dividend yield of 5.29 percent on a declared dividend of $0.49. The payout ratio is 51.6 percent.

Bristol-Myers Squibb Co (BMY) has a dividend yield of 4.70 percent on a declared dividend of $0.33. The payout ratio is 57.0 percent.

Merck & Co Inc (MRK) has a dividend yield of 4.23 percent on a declared dividend of $0.38. The payout ratio is 113.1 percent.

Pfizer Inc (PFE) has a dividend yield of 3.81 percent on a declared dividend of $0.20. The payout ratio is 49.8 percent.

Abbott Laboratories (ABT) has a dividend yield of 3.69 percent on a declared dividend of $0.48. The payout ratio is 79.4 percent.

Microsoft (MSFT) Patent Battle Has Companies, Industries Choosing Sides

The battle by Microsoft (NASDAQ:MSFT) to make it easier to challenge whether or not a patent is valid or not is heading to the Supreme Court, as various companies and industries line up on both sides of the issue in support of or against the case.

Backing Microsoft are many in the tech sector, including Google Inc. (NASDAQ:GOOG), Verizon Communications Inc. (NYSE:VZ), Apple Inc. (NASDAQ:AAPL), Cisco Systems Inc. (NASDAQ:CSCO), eBay Inc. (NASDAQ:EBAY), Facebook Inc. and Intel Corp. (NASDAQ:INTC), while lining up against them are 3M Co. (NYSE:MMM), Johnson & Johnson (NYSE:JNJ) and General Electric Co. (NYSE:GE), along with branded drug companies like Pfizer (NYSE:PFE) and Merck (NYSE:MRK).

Companies supporting Microsoft said in a brief, "Those allegations are often based on invalid patents, but they are nonetheless costly and risky to defend, in part because of the clear-and-convincing standard."

Companies opposing Microsoft noted, "Inventors and society would suffer from such a rule, which would simultaneously reduce the rewards of innovation by weakening property rights while increasing the costs of innovation."

Banks and other financial companies also support Microsoft, as they are often recipients of lawsuits in regard to patents as well.

Sanofi-Aventis (NYSE:SNY) Gets Positive Feedback from Genzyme for Alemtuzumab

Sanofi-Aventis (NYSE: SNY) received positive data from Genzyme concerning a phase 2 clinical trial for its experimental multiple sclerosis medication, alemtuzumab. The estimated value of the drug candidate was a key sticking point in the negotiations between the biotechnology company and its acquirer. In the final $20.1 billion acquisition deal, completed earlier this month, Sanofi agreed to provide Genzyme shareholders with conditional payments based on milestones connected with the drug, as well as with other drugs in Genzyme’s stable.

Genzyme executives noted that additional five-year patient data from its completed Phase 2 trial showing that almost two-thirds of patients “remained free of clinically-active disease as much as four years after most patients received their last course of the investigational drug.” These new data were presented at the American Academy of Neurology’s annual meeting in Hawaii.

The trial compared alemtuzumab, which would be marketed under the name Lemtrada, if approved, to the approved MS therapy Rebif, made by EMD Serono and Pfizer (NYSE:PFE). The new data reveals that 65 percent of alemtuzumab-treated patients were free of clinically-active disease, compared to 27 percent of patients taking Rebif. What this means that for five years, those two-thirds of patients did not suffer any relapses or have a sustained increase in disability, as measured by the Expanded Disability Status Scale.

The data also showed patients taking Genzyme’s drugs were twice as likely to see a sustained improvement in their vision, a common complication of the disease, as were those using Rebif.

Two phase 3 studies on the drug candidate are currently underway. Sanofi plans to file for U.S. Food and Drug Administration approval for alemtuzumab in early 2012. Alemtuzumab has been granted fast track status, meaning that the review time will be shortened to six-months.

Sanofi-Aventis was trading at $37.31, up $0.22, or 0.59 percent, as of 2:39 PM EDT.